Viridian Therapeutics (VRDN) risk factors, FY2025 10-K

Risks Related to Our Financial Condition and Capital Requirements

1. 01We have historically incurred losses, have a limited operating history on which to assess our business, and anticipate that we will continue to incur significant losses for the foreseeable future24% rewritten
2. 02If we are unable to raise capital when needed, we would be forced to delay, reduce, or eliminate our research and product development programs or future commercialization efforts30% rewritten
3. 03We have never generated any revenue from product sales and may never be profitable
4. 04Raising additional capital may cause dilution to our stockholders, restrict our operations, or require us to relinquish rights
5. 05Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses
6. 06We may not be entitled to obtain additional milestone payments under the DRI Purchase and Sale AgreementNew

Risks Related to the Discovery and Development of Our Product Candidates

1. 07Clinical trials are costly, time consuming, and inherently risky, and we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities
2. 08Even if we obtain regulatory approval for a product candidate, we will remain subject to ongoing regulatory requirements
3. 09Regulatory approval processes are lengthy, time-consuming and inherently unpredictable. Failure to obtain regulatory approval for our product candidates would have a material adverse effect upon our business and business prospects25% rewritten
4. 10Failure to obtain regulatory approval for our product candidates would have a material adverse effect upon our business and business prospectsNew
5. 11Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial viability of approved labeling, or result in significant negative consequences following marketing approval, if any79% rewritten
6. 12result in reduced market acceptance and utilization of our product or potential product liability claims. Any of these occurrences may materially harm our business, financial condition, results of operations and prospectsNew
7. 13Additional time may be required to obtain marketing authorizations for certain of our product candidates because they are, or are anticipated to be, combination products
8. 14Product development involves a lengthy and expensive process with an uncertain outcome, and results of earlier nonclinical studies and clinical trials may not be predictive of future clinical trial results
9. 15Preliminary data from our clinical trials that we announce or publish are subject to audit and verification procedures that could result in material changes in the final data37% rewritten
10. 16We may use our financial and human resources to pursue a particular research program or product candidate and fail to capitalize on programs or product candidates that may be more profitable or for which there is a greater likelihood of success71% rewritten
11. 17As a result of these factors, a product liability claim, even if successfully defended, could have a material adverse effect on our business, financial condition, or results of operations

Risks Related to Commercialization of Our Product Candidates

1. 18Our business operations and market access arrangements will be subject to applicable healthcare regulatory laws, which, if not properly adhered to, could expose us to penaltiesNew
2. 19The distribution of biopharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical productsNew
3. 20If we are unable to establish commercial manufacturing, sales and marketing capabilities or enter into agreements with third parties to commercially manufacture, market and sell our product candidates, we may be unable to generate any revenue49% rewritten
4. 21We may attempt to form collaborations in the future with respect to our product candidates, but we may not be able to do so, which may cause us to alter our development and commercialization plans. Even where we have entered into a collaboration, they may not be successful
5. 22We face substantial competition, and our competitors may discover, develop, or commercialize products faster or more successfully than us
6. 23If our competitors obtain marketing approval from the FDA, EMA, or comparable foreign regulatory authorities for their product candidates more rapidly than us, it could result in our competitors establishing a strong market position before we are able to enter the market
7. 24Our products may not be widely adopted by patients, payors or healthcare providers, which would adversely impact our potential profitability and future business prospects
8. 25Failure to obtain or maintain adequate pricing, reimbursement or insurance coverage for our products, if any, could limit our ability to market those products and decrease our ability to generate revenue45% rewritten
9. 26If we are unable to successfully further develop and maintain internal commercialization capabilities, sales of our future products may be negatively impacted33% rewritten
10. 27If we are not successful in establishing an effective commercial, sales and marketing infrastructure, we will encounter difficulty in achieving, maintaining or increasing projected sales of our products, if approved, which would adversely affect our business and financial conditionNew

Risks Related to Our Reliance on Third Parties

1. 28Our manufacturing processes are complex, and we may encounter difficulties in production, which would delay or prevent our ability to provide a sufficient clinical or commercial supply of our product candidates or products
2. 29In addition, we rely on third parties to perform release testing on our product candidates prior to delivery to patients. If these tests are not appropriately conducted and test data are not reliable, patients could be put at risk of serious harm, and this could result in product liability suits33% rewritten
3. 30We may be unable to realize the potential benefits of any collaboration

Risks Related to Our Intellectual Property

1. 31We may not have sufficient patent term protections for our product candidates to effectively protect our business89% rewritten
2. 32impact our business, financial condition, results of operations, and prospects. If we do not have sufficient patent terms or regulatory exclusivity to protect our product candidates, our business and results of operations will be adversely affectedNew
3. 33If we are unable to maintain effective proprietary rights for our product candidates or any future product candidates, we may not be able to compete effectively in our proposed markets
4. 34Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts80% rewritten
5. 35The patent protection and patent prosecution for some of our product candidates are dependent on third parties
6. 36Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
7. 37If we fail to comply with obligations in the agreements under which we license intellectual property and other rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business, which would harm our business
8. 38We may be involved in lawsuits or post-grant review proceedings to defend, protect, or enforce our patents or the patents of our licensors, which could be expensive, time consuming, and unsuccessful80% rewritten
9. 39We may be subject to claims challenging the inventorship of our patents and other intellectual property
10. 40We may not be able to protect our intellectual property rights throughout the world55% rewritten

Risks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters

1. 41We expect the product candidates we develop will be regulated as biologics, and they may be subject to competition from biosimilar and interchangeable biological products
2. 42We may seek orphan drug designation for our product candidates, but we might not receive such designationNew
3. 43We may seek Fast Track, Breakthrough Therapy, and/or Priority Review designations for one or more of our product candidates, but we might not receive such designation(s), and even if we do, such designation(s) may not actually lead to a faster development or regulatory review or approval process51% rewritten
4. 44Any of the above occurrences could reduce or eliminate sales of our approved products, increase our expenses and impair our ability to successfully commercialize one or more of these productsNew
5. 45We may be subject, directly or indirectly, to a wide range of domestic and foreign healthcare and other laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties, sanctions, or other liability75% rewritten
6. 46If we fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business, financial condition, or results of operations
7. 47Our use of artificial intelligence (AI) or other emerging technologies could adversely impact our business and financial results

Risks Related to Our Business Operations

1. 48Our future success depends in part on our ability to attract, retain, and motivate qualified personnel. If we lose key personnel, or if we fail to recruit additional highly skilled personnel, our ability to develop our product candidates will be impaired and our business may be harmed
2. 49We will need to expand our organization and we may experience difficulties in managing this growth, which could disrupt our operations
3. 50The Hercules Loan and Security Agreement contains certain covenants that could adversely affect our operations and, if an event of default were to occur, we could be forced to repay any outstanding indebtedness sooner than planned and possibly at a time when we do not have sufficient capital to meet this obligation
4. 51Failure in our information technology and storage systems, or those of third parties upon whom we rely, could significantly disrupt the operation of our business and adversely impact our financial condition
5. 52Furthermore, parties in our supply chain may be operating from single sites, increasing their vulnerability to natural disasters or other sudden, unforeseen, and severe adverse events. If such an event were to affect our supply chain, it could have a material adverse effect on our business
6. 53Our ability to use net operating loss carryforwards and certain other tax attributes to offset future taxable income or taxes may be limited
7. 54Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition, or results of operations
8. 55Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of accrued amounts

Risks Related to Ownership of our Common Stock

1. 56Anti-takeover provisions in our charter documents and under Delaware law and the terms of some of our contracts could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our management
2. 57Our Bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or other employees
3. 58We do not anticipate that we will pay any cash dividends in the foreseeable future
4. 59Future sales of shares by existing stockholders could cause our stock price to decline
5. 60Future sales and issuances of equity and debt could result in additional dilution to our stockholders
6. 61Our principal stockholders own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval
7. 62The market price of our common stock has historically been volatile, and the market price of our common stock may drop in the future
8. 63We may be subject to risks related to litigation and other legal proceedings that may materially adversely affect our business, operating results or financial condition
9. 64We incur costs and demands upon management as a result of complying with the laws and regulations affecting public companies
10. 65If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business, or our market, our stock price and trading volume could decline
11. 66If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our common stock may be negatively affected
12. 67Our inability to maintain effective internal control over financial reporting in the future could result in investors losing confidence in the accuracy and completeness of our financial reports and negatively affect the market price of our common stock